Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 5Phase 1/2 4Phase 3 3Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 15Head & Neck 5Lymphoid 4Gastrointestinal 4Tumor-Agnostic 1Other neoplasm 1NET 1Myeloid 1Gynecologic 1Endocrine 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Cisplatin × Endocrine × Clear all
NCT06485739 2024-07-03

Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma

First Affiliated Hospital Xi'an Jiaotong University

Phase 4 Not yet recruiting
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡